Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 1 | BMC Immunology

Fig. 1

From: Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist

Fig. 1

Optimization of Imiquimod (IMQ)-induced Psoriasis Model for Exhibiting Efficacy of Interleukin-17A Antibody on C57BL/6 Mice. a Skin damage (on day 5 of experiment) and b disease severity of 62.5 mg IMQ induced-psoriasis in mice. c Protective effect of Dexamethasone (10 mg/kg, daily) on 62.5 mg IMQ-induced psoriasis in mice. Effect of IMQ in different dosages on d disease severity and e bodyweight of mice. f Protective effect of Anti-IL17A antibody in different dosages (0.1–1 mg/kg) on IMQ (42 mg) induced psoriasis. “PASI Score” plot indicated disease severity evaluated by Psoriasis Area Severity Index (PASI) system (n = 6). Data was expressed as mean ± SEM, Anti-IL17A, Anti-IL17A antibody; Dex, Dexamethasone

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us